ArticleBiomolecules & biomedicine2026
Serum gelsolin as a biomarker for differentiating familial Mediterranean fever from juvenile idiopathic arthritis in children.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gelsolin (Gsn), an actin-binding protein implicated in cytoskeletal remodeling and the regulation of inflammation, has emerged as a potential biomarker for immune-mediated and inflammatory diseases. This prospective case-control study aimed to evaluate serum Gsn levels in children diagnosed with juvenile idiopathic arthritis (JIA) and familial Mediterranean fever (FMF) and to assess its potential utility in differentiating between these two pediatric rheumatic disorders. The study involved 90 children aged 2-18 years: 30 with JIA, 30 with FMF, and 30 age-matched healthy controls. Serum Gsn concentrations were quantified using enzyme-linked immunosorbent assay (ELISA), and both clinical and laboratory parameters were analyzed. Mean serum Gsn levels were highest in the FMF group (28.8 ± 2.5), followed by the JIA group (25.7 ± 2.8) and healthy controls (23.9 ± 2.7), with significant differences observed among the groups (p < 0.001). Gsn levels were significantly elevated in children with FMF compared to those with JIA, and receiver operating characteristic (ROC) analysis demonstrated strong discriminatory performance, with an area under the curve (AUC) of 0.82. Logistic regression analysis identified serum Gsn, aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) as independent predictors for distinguishing FMF from JIA. Each unit increase in Gsn was associated with increased odds of an FMF diagnosis (odds ratio [OR]: 2.89, 95% confidence interval [CI]: 1.58-5.29, p = 0.001). These findings suggest that serum Gsn may serve as a valuable biomarker in pediatric inflammatory rheumatic diseases, particularly in differentiating FMF from JIA. Further large-scale prospective studies are necessary to validate its diagnostic effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.